Eiger BioPharmaceuticals - EIGR Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EIGR shares.
View EIGR analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued twelve-month price targets for Eiger BioPharmaceuticals' stock. Their EIGR share price forecasts range from $3.00 to $9.00. On average, they predict the company's share price to reach $5.33 in the next year. This suggests a possible upside of 281.0% from the stock's current price.
View analysts price targets for EIGR or view top-rated stocks among Wall Street analysts.

Eiger BioPharmaceuticals' stock was trading at $1.18 at the beginning of 2023. Since then, EIGR shares have increased by 18.6% and is now trading at $1.40.
View the best growth stocks for 2023 here.

Eiger BioPharmaceuticals saw a drop in short interest in the month of January. As of January 15th, there was short interest totaling 1,200,000 shares, a drop of 21.1% from the December 31st total of 1,520,000 shares. Based on an average trading volume of 905,700 shares, the days-to-cover ratio is currently 1.3 days.
View Eiger BioPharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our EIGR earnings forecast.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) posted its quarterly earnings results on Thursday, November, 3rd. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by $0.07. The biotechnology company earned $4.02 million during the quarter, compared to analyst estimates of $3.93 million. Eiger BioPharmaceuticals had a negative trailing twelve-month return on equity of 106.48% and a negative net margin of 660.21%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Eiger BioPharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (1.44%), DAVENPORT & Co LLC (0.53%) and Sigma Planning Corp (0.26%). Insiders that own company stock include David Apelian, Eldon C Mayer III, Evan Loh, Jeffrey S Glenn, Sriram Ryali and Thomas John Dietz.
View institutional ownership trends.

Shares of EIGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EIGR stock can currently be purchased for approximately $1.40.

Eiger BioPharmaceuticals (NASDAQ:EIGR) has a market capitalization of $61.70 million and generates $12.14 million in revenue each year. The biotechnology company earns $-33,920,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis.

Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The official website for the company is www.eigerbio.com. The biotechnology company can be reached via phone at (650) 272-6138, via email at ichoong@eigerbio.com, or via fax at 650-618-1621.